A single-arm, multi-center trial evaluating thin-strut DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System.
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2016
At a glance
- Drugs Novolimus (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms DESolve™ Cx
- 14 Nov 2016 New trial record
- 01 Nov 2016 According to an Elixir Medical Corporation Media Release, six-month results of the entire study population will be presented after follow-up completion.
- 01 Nov 2016 Interim results (n=25) published in an Elixir Medical Corporation Media Release.